Introduction {#sec1}
============

Ovarian cancer contributes to most of the deaths from all gynecologic malignancies. It is the fifth leading cause of female health problems and deaths all over the world due to cancer \[[@B1]\]. Mostly ovarian cancer patients are diagnosed at an advanced stage; in recent years combined treatment of debulking surgery and chemotherapy have yielded a modest improvement in survival as a standard therapy \[[@B2]\]. Ovarian cancers predominantly have epithelial origins and are further classified into histological groups such as serous, clear cell, endometrioid, mucinous, transitional cell tumors, carcinosarcoma, undifferentiated carcinoma, mixed epithelial tumor, and so on \[[@B3]\]. Although considerable advances are present in early detection, chemotherapy, radical cure surgery, and targetted therapeutic management, many cases still (approximately 85%) recur \[[@B4]\] and develop gradual treatment resistance with lower 5-year survival rate (30%) \[[@B5]\]. Therefore, early establishment of a novel prognostic marker in ovarian cancer is the urgent requirement for the better prognosis and to improve clinical outcomes of these patients.

Aquaporins (AQPs) are a family of integral membrane proteins, which regulate the selective transport of water and other ions across membranes in response to osmotic or pressure gradient \[[@B6]\]. So far, 13 different types of AQPs have been identified. AQP0, AQP1, AQP2, AQP4, AQP5, AQP6, and AQP8 are mainly water-selective permeable to anions and ammonia \[[@B7],[@B8]\], whereas AQP3, AQP7, AQP9, AQP10, and AQP12 also transport glycerol and possibly other small solutes, and AQP11 is not clear even as a water channel due to its unusual location in the cell \[[@B9],[@B10]\]. Apart from its classical role as osmotic transepithelial and transcellular water regulators, AQPs are also involved in carcinogenesis of multiple cancers leading to tumor angiogenesis, cell migration, tumor progression, and tumor growth \[[@B9],[@B11],[@B12]\]. In particular, combined evidences have reported that AQPs could be used as an independent cancer prognostic factor and represent a potential target for different cancer therapy \[[@B13]\]. However, the prognostic values of *AQPs* mRNA expression in ovarian cancer have not been determined. In the present study, to demonstrate whether individual AQP genes are involved in prognostic significance of human ovarian cancer patients including various clinicopathological features such as pathological grade, clinical stage, TP53 status, and treatment strategy, we comprehensively explored data by using the Kaplan--Meier plotter (KM plotter).

Materials and methods {#sec2}
=====================

An online KM plotter (<http://kmplot.com/analysis>) \[[@B16]\] database was utilized to evaluate relevant searches of individual AQPs members' mRNA expression to overall survival (OS) of ovarian cancer patients. Recently, KM plotter is established with the potential access to 54675 genes that have been identified and validated in breast cancer \[[@B16]\], ovarian cancer \[[@B19],[@B20]\], lung cancer \[[@B21]\], and gastric cancer \[[@B22]\]. In this study, 1816 ovarian cancer patients gene expressions and data on prognostic roles were established from Gene Expression Omnibus, Cancer Biomedical Informatics Grid, and The Cancer Genome Atlas cancer datasets \[[@B20]\]. Moreover, they provided the clinical data including stage, grade, histology, TP53 mutation status, and treatment of ovarian cancer patients. In the present study, from the available data source, we collected clinical outcomes such as pathological grades, clinical stages, TP53 status and chemotherapeutic strategy. In short, 11 AQP submembers (AQP0, AQP1, AQP2, AQP3, AQP4, AQP5, AQP6/2L, AQP8, AQP9, AQP10, and AQP11) were entered into the database (<http://kmplot.com/analysis/index.php?p=service&cancer=ovar>) to achieve Kaplan--Meier survival plots. Hazard ratio (HR) and 95% confidence intervals as well as log-rank *P* were calculated and displayed on the web page. A *P*-value of \<0.05 was regarded as statistically significant.

Results {#sec3}
=======

Amongst 13 different subtypes of AQPs, only data on 11 members were pooled in [www.kmplot.com](http://www.kmplot.com) ([Figure 1](#F1){ref-type="fig"}). Initially, the prognostic value of AQP0 was accessed in the database. For AQP0, Affymetrix ID is 220863_at. OS curves were plotted for all ovarian cancer patients (*n*=1656) ([Figure 2](#F2){ref-type="fig"}A), for serous cancer patients (*n*=1207) ([Figure 2](#F2){ref-type="fig"}B) and endometrioid cancer patients (*n*=37) ([Figure 2](#F2){ref-type="fig"}C). Elevated expression of *AQP0* mRNA was significantly associated with poor OS in all ovarian cancer patients, HR = 1.15 (1.01--1.31), *P*=0.029. However, high expression of *AQP0* mRNA in endometrioid ovarian cancer patients displayed better OS, HR = 0.1 (0.01--0.89), *P*=0.011, while in serous ovarian cancer patients showed no any correlation with OS, HR = 1.16 (0.98--1.37), *P*=0.09.

![The prognostic HRs value of individual AQPs members in all ovarian cancer in [www.kmplot.com](http://www.kmplot.com)](bsr-38-bsr20180108-g1){#F1}

![The prognostic value of AQP0 expression in ovarian cancer\
The prognostic value of AQP0 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP0: 220863_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g2){#F2}

Next, the prognostic significance of *AQP1* mRNA expression was evaluated in the database. The desired Affymetrix ID is 209047_at. *AQP1* mRNA expression level revealed a remarkable correlation with worse OS amongst all the ovarian cancer patients, HR = 1.21 (1.06--1.38), *P*=0.0036 ([Figure 3](#F3){ref-type="fig"}A). The histological subtype results showed that increased *AQP1* mRNA expression highly associated with unfavorable OS in patients of serous ovarian cancer, HR = 1.3 (1.12--1.52), *P*=0.00071 ([Figure 3](#F3){ref-type="fig"}B), whereas expression level of *AQP1* mRNA in endometrioid cancer patient did not show any correlation with OS, HR = 2.65 (0.3--23.7), *P*=0.37 ([Figure 3](#F3){ref-type="fig"}C).

![The prognostic value of AQP1 expression in ovarian cancer\
The prognostic value of AQP1 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP1: 209047_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g3){#F3}

Similarly, for AQP2 Affymetrix ID is 236630_at. *AQP2* mRNA expression exhibited a null correlation with OS within all ovarian cancer patients as well as in serous and endometrioid histological subgroups, HR = 1.13 (0.92--1.38), *P*=0.25 ([Figure 4](#F4){ref-type="fig"}A), HR = 1.17 (0.93--1.46), *P*=0.18 ([Figure 4](#F4){ref-type="fig"}B) and HR = 3.01 (0.31--29), *P*=0.32 ([Figure 4](#F4){ref-type="fig"}C), respectively.

![The prognostic value of AQP2 expression in ovarian cancer\
The prognostic value of AQP2 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP2: 236630_at. OS curves were plotted for (**A**) all the patients (*n*=655), (**B**) serous cancer patients (*n*=523), and (**C**) endometrioid cancer patients (*n*=30).](bsr-38-bsr20180108-g4){#F4}

Then the prognostic value of AQP3 was further determined in the database. The Affymetrix ID is 39248_at. *AQP3* mRNA expression was significantly correlated with better OS for all ovarian cancer patients, HR = 0.77 (0.67--0.89), *P*=0.00043 ([Figure 5](#F5){ref-type="fig"}A), serous ovarian cancer patients, HR = 0.82 (0.7--0.95), *P*=0.01 ([Figure 5](#F5){ref-type="fig"}B), and endometrioid ovarian cancer patients, HR = 0.15 (0.03--0.93), *P*=0.019 ([Figure 5](#F5){ref-type="fig"}C).

![The prognostic value of AQP3 expression in ovarian cancer\
The prognostic value of AQP3 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP3: 39248_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g5){#F5}

[Figure 6](#F6){ref-type="fig"} demonstrated the prognostic value of AQP4 in the database. The Affymetrix ID for AQP4: 226228_at. Increased expression of *AQP4* mRNA was significantly correlated with poor OS for all ovarian cancer, HR = 1.54 (1.2--1.97), *P*=0.00062 ([Figure 6](#F6){ref-type="fig"}A) and serous ovarian cancer, HR = 1.55 (1.17--2.05), *P*=0.0022 ([Figure 6](#F6){ref-type="fig"}B). However, overexpression of *AQP4* mRNA for endometrioid ovarian cancer was not correlated with OS, HR = 1171517663.86 (0--inf), *P*=0.097 ([Figure 6](#F6){ref-type="fig"}C).

![The prognostic value of AQP4 expression in ovarian cancer\
The prognostic value of AQP4 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP4: 226228_at. OS curves were plotted for (**A**) all the patients (*n*=655), (**B**) serous cancer patients (*n*=523), and (**C**) endometrioid cancer patients (*n*=30).](bsr-38-bsr20180108-g6){#F6}

[Figure 7](#F7){ref-type="fig"} illustrated the prognostic value of AQP5 in the database. Affymetrix IDs for AQP5: 213611_at. The higher expression of *AQP5* mRNA level was associated with better OS in all ovarian cancer patients, HR = 0.84 (0.73--0.97), *P*=0.015 ([Figure 7](#F7){ref-type="fig"}A). Nevertheless, *AQP5* mRNA expression both in serous ovarian cancer and endometrioid ovarian cancer did not show any correlation with OS, HR = 0.92 (0.78--1.08), *P*=0.31 ([Figure 7](#F7){ref-type="fig"}B), and HR = 0.19 (0.02--1.73), *P*=0.1 ([Figure 7](#F7){ref-type="fig"}C), respectively.

![The prognostic value of AQP5 expression in ovarian cancer\
The prognostic value of AQP5 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP5: 213611_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g7){#F7}

AQP6 is also known as AQP2L. [Figure 8](#F8){ref-type="fig"} showed the prognostic significance of AQP6 in the database. Affymetrix ID for AQP6/AQP2L is 216219_at. The elevated expression of *AQP6/AQP2L* mRNA was associated with favorable OS for all ovarian cancer patients and endometrioid ovarian cancer patients, HR = 0.83 (0.73--0.94), *P*=0.0045 ([Figure 8](#F8){ref-type="fig"}A), HR = 0.12 (0.01--1.1), *P*=0.025 ([Figure 8](#F8){ref-type="fig"}C), respectively. While outcome measures regarding serous ovarian cancer, *AQP6/AQP2L* mRNA showed no any correlation with OS, HR = 0.86 (0.73--1.01), *P*=0.066 ([Figure 8](#F8){ref-type="fig"}B).

![The prognostic value of AQP6 expression in ovarian cancer\
The prognostic value of AQP6 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP6: 216219_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g8){#F8}

[Figure 9](#F9){ref-type="fig"} presented the prognostic value of *AQP8* mRNA expression in the database. Affymetrix ID for AQP8 was 206784_at. Overexpression of AQP8 was significantly correlated with favorable OS in all ovarian cancer patients, HR = 0.85 (0.73--0.98), *P*=0.024 ([Figure 9](#F9){ref-type="fig"}A). However, it did not show any correlation with OS in serous and endometrioid ovarian cancer patients, HR = 1.1 (0.95--1.29), *P*=0.21 ([Figure 9](#F9){ref-type="fig"}B), HR = 0.42 (0.07--2.5), *P*=0.32 ([Figure 9](#F9){ref-type="fig"}C), respectively.

![The prognostic value of AQP8 expression in ovarian cancer\
The prognostic value of AQP8 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP8: 206784_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g9){#F9}

[Figure 10](#F10){ref-type="fig"} revealed the prognostic value of *AQP9* mRNA expression in the database. Affymetrix ID for AQP9 is 205568_at. Higher expression of AQP9 was neither correlated with OS for all ovarian cancer HR = 0.91 (0.8--1.05), *P*=0.19 ([Figure 10](#F10){ref-type="fig"}A) nor with serous, HR = 0.9 (0.77--1.05), *P*=0.18 ([Figure 10](#F10){ref-type="fig"}B) and endometrioid cancer, HR = 0 (0--inf), *P*=0.076 ([Figure 10](#F10){ref-type="fig"}C).

![The prognostic value of AQP9 expression in ovarian cancer\
The prognostic value of AQP9 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP9: 205568_at. OS curves were plotted for (**A**) all the patients (*n*=1656), (**B**) serous cancer patients (*n*=1207), and (**C**) endometrioid cancer patients (*n*=37).](bsr-38-bsr20180108-g10){#F10}

[Figure 11](#F11){ref-type="fig"} showed the prognostic value of *AQP10* mRNA expression in the database. Affymetrix ID for AQP10 was 1555338_s\_at. AQP10's high mRNA expression was found to be associated with better OS for all ovarian cancer patients, HR = 0.72 (0.57--0.9), *P*=0.0039 ([Figure 11](#F11){ref-type="fig"}A). Furthermore, high *AQP10* mRNA expression was also correlated with better OS for serous ovarian cancer patients, HR = 0.71 (0.56--0.91), *P*=0.0073 ([Figure 11](#F11){ref-type="fig"}B). However, the expression level of AQP10 was not correlated with endometrioid ovarian cancer, HR = 0.32 (0.03--3.08), *P*=0.3 ([Figure 11](#F11){ref-type="fig"}C).

![The prognostic value of AQP10 expression in ovarian cancer\
The prognostic value of AQP10 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP10: 1555338_s\_at. OS curves were plotted for (**A**) all the patients (*n*=655), (**B**) serous cancer patients (*n*=523), and (**C**) endometrioid cancer patients (*n*=30).](bsr-38-bsr20180108-g11){#F11}

Finally, we assessed the prognostic significance of *AQP11* mRNA expression in the database. Affymetrix IDs for AQP11 was 229526_at. High level of *AQP11* mRNA was significantly associated with better OS for all ovarian cancer patients, HR = 0.78 (0.63--0.95), *P*=0.015 ([Figure 12](#F12){ref-type="fig"}A) and serous ovarian cancer, HR = 0.7 (0.56--0.88), *P*=0.0021 ([Figure 12](#F12){ref-type="fig"}B). However, increased *AQP11* mRNA in endometrioid ovarian cancer was not associated with OS, HR = 5.24 (0.54--50.47), *P*=0.11 ([Figure 12](#F12){ref-type="fig"}C).

![The prognostic value of AQP11 expression in ovarian cancer\
The prognostic value of AQP11 expression in [www.kmplot.com](http://www.kmplot.com). Affymetrix ID for AQP11: 229526_at. OS curves were plotted for (**A**) all the patients (*n*=655), (**B**) serous cancer patients (*n*=523), and (**C**) endometrioid cancer patients (*n*=30).](bsr-38-bsr20180108-g12){#F12}

In the present study, constitutive expression of *AQP2* and *AQP9* mRNA showed not any correlation to the prognosis of all ovarian cancer patients, serous ovarian cancer patients, as well as endometrioid ovarian cancer patients. Therefore, the associations of the other nine AQP submembers mRNA with other clinicopathological features were further examined, including the pathological grades ([Table 1](#T1){ref-type="table"}), clinical stages ([Table 2](#T2){ref-type="table"}), TP53 mutation ([Table 3](#T3){ref-type="table"}) and chemotherapy agents ([Table 4](#T4){ref-type="table"}) of ovarian cancer patients. As shown in the [Table 1](#T1){ref-type="table"}, overexpression of AQP3, AQP6/2L, and AQP11 were associated with favorable OS in grade III ovarian cancer patients. Subsequent expression of *AQP0, AQP5*, and *AQP10* mRNA expression had better OS in grade I ovarian cancer patients. On the other hand, mRNA expression of AQP1 (grades I and II), AQP4 (grades I, II, and III), AQP6/2L (grade I), AQP10 (grade II) showed a worse OS in ovarian cancer patients. Whereas, *AQP8* mRNA expression showed not any correlation with all pathological grade of ovarian cancer.

###### Correlation of AQPs gene expression level with OS in different pathological grades in ovarian cancer patients

  AQPs         Pathological grade   Cases   HR (95% CI)          *P*-value
  ------------ -------------------- ------- -------------------- -------------------------------------------
  AQP0         I                    56      0.26 (0.09--0.75)    0.0076[\*](#T1TFN1){ref-type="table-fn"}
               II                   324     1.2 (0.88--1.63)     0.25
               III                  1015    1.1 (0.93--1.31)     0.26
  AQP1         I                    56      2.77 (0.99--7.76)    0.044[\*](#T1TFN1){ref-type="table-fn"}
               II                   324     1.49 (1.1-- 2.01)    0.0094[\*](#T1TFN1){ref-type="table-fn"}
               III                  1015    1.15 (0.97--1.36)    0.12
  AQP3         I                    56      0.4 (0.14--1.12)     0.07
               II                   324     0.79 (0.56--1.11)    0.17
               III                  1015    0.81 (0.68--0.95)    0.01[\*](#T1TFN1){ref-type="table-fn"}
  AQP4         I                    41      5.21 (1.43--18.97)   0.0055[\*](#T1TFN1){ref-type="table-fn"}
               II                   162     2.01 (1.26--3.22)    0.0028[\*](#T1TFN1){ref-type="table-fn"}
               III                  392     1.49 (1.1--2.02)     0.0093[\*](#T1TFN1){ref-type="table-fn"}
  AQP5         I                    56      0.37 (0.14--0.99)    0.04[\*](#T1TFN1){ref-type="table-fn"}
               II                   324     1.27 (0.93--1.72)    0.13
               III                  1015    0.91 (0.77--1.08)    0.29
  AQP6/AQP2L   I                    56      2.68 (1.02--7.05)    0.038[\*](#T1TFN1){ref-type="table-fn"}
               II                   324     0.77 (0.57--1.05)    0.093
               III                  1015    0.83 (0.71--0.99)    0.034[\*](#T1TFN1){ref-type="table-fn"}
  AQP8         I                    56      0.34 (0.1--1.18)     0.075
               II                   324     0.77 (0.56--1.06)    0.11
               III                  1015    0.85 (0.7--1.02)     0.081
  AQP10        I                    41      0.14 (0.04--0.46)    0.00021[\*](#T1TFN1){ref-type="table-fn"}
               II                   162     1.67 (1.04--2.67)    0.031[\*](#T1TFN1){ref-type="table-fn"}
               III                  392     0.76 (0.57--1)       0.051
  AQP11        I                    41      2.12 (0.66--6.79)    0.19
               II                   162     0.66 (0.42--1.02)    0.057
               III                  392     0.7 (0.55--0.91)     0.0067[\*](#T1TFN1){ref-type="table-fn"}

*P*\<0.05.

###### Correlation of AQPs gene expression level with OS in different clinical stages in ovarian cancer patients

  AQPs         Clinical stages   Cases   HR (95% CI)          *P*-value
  ------------ ----------------- ------- -------------------- -------------------------------------------
  AQP0         I + II            135     0.49 (0.21--1.13)    0.088
               III + IV          1220    0.92 (0.78--1.09)    0.34
  AQP1         I + II            135     2.16 (0.98--4.77)    0.05[\*](#T2TFN1){ref-type="table-fn"}
               III + IV          1220    1.19 (1.02--1.39)    0.027[\*](#T2TFN1){ref-type="table-fn"}
  AQP3         I + II            135     0.62 (0.27--1.43)    0.26
               III + IV          1220    0.82 (0.69--0.97)    0.017[\*](#T2TFN1){ref-type="table-fn"}
  AQP4         I + II            83      5.97 (0.78--45.49)   0.05[\*](#T2TFN1){ref-type="table-fn"}
               III + IV          487     1.39 (1.09--1.77)    0.0072[\*](#T2TFN1){ref-type="table-fn"}
  AQP5         I + II            135     6.33 (1.48--27.11)   0.0047[\*](#T2TFN1){ref-type="table-fn"}
               III + IV          1220    0.85 (0.72--1)       0.054
  AQP6/AQP2L   I + II            135     0.43 (0.19--0.95)    0.032[\*](#T2TFN1){ref-type="table-fn"}
               III + IV          1220    0.75 (0.65--0.88)    0.00024[\*](#T2TFN1){ref-type="table-fn"}
  AQP8         I + II            135     0.52 (0.24--1.14)    0.096
               III + IV          1220    0.77 (0.65--0.91)    0.0024[\*](#T2TFN1){ref-type="table-fn"}
  AQP10        I + II            83      0.37 (0.12--1.17)    0.079
               III + IV          487     0.69 (0.53--0.89)    0.0041[\*](#T2TFN1){ref-type="table-fn"}
  AQP11        I + II            83      0.56 (0.16--1.97)    0.36
               III + IV          487     0.84 (0.67--1.05)    0.12

*P*\<0.05.

###### Correlation of AQPs genes expression with OS in ovarian cancer patients with TP53 mutation status

  AQPs         TP53 mutation   Cases   HR (95% CI)         *P*-value
  ------------ --------------- ------- ------------------- ------------------------------------------
  AQP0         Mutant          506     1.16 (0.91--1.49)   0.22
               Wild            94      1.55 (0.9--2.67)    0.11
  AQP1         Mutant          506     1.38 (1.1--1.73)    0.0051[\*](#T3TFN1){ref-type="table-fn"}
               Wild            94      1.87 (1.03--3.4)    0.036[\*](#T3TFN1){ref-type="table-fn"}
  AQP3         Mutant          506     1.16 (0.93--1.47)   0.19
               Wild            94      1.39 (0.8--2.4)     0.24
  AQP4         Mutant          124     1.75 (1.18--2.59)   0.0045[\*](#T3TFN1){ref-type="table-fn"}
               Wild            19      Not available       Not available
  AQP5         Mutant          506     0.82 (0.65--1.04)   0.1
               Wild            94      0.76 (0.42--1.39)   0.38
  AQP6/AQP2L   Mutant          506     0.84 (0.65--1.07)   0.16
               Wild            94      0.56 (0.3--1.02)    0.056
  AQP8         Mutant          506     1.33 (1.06--1.67)   0.013[\*](#T3TFN1){ref-type="table-fn"}
               Wild            94      1.41 (0.82--2.42)   0.21
  AQP10        Mutant          124     0.74 (0.49--1.12)   0.16
               Wild            19      Not available       Not available
  AQP11        Mutant          124     1.31 (0.9--1.91)    0.16
               Wild            19      Not available       Not available

*P*\<0.05.

###### Correlation of AQPs genes expression level with OS in ovarian cancer patients with different chemotherapeutic agents

  AQPs         Chemotherapy              Cases   HR (95% CI)         *P*-value
  ------------ ------------------------- ------- ------------------- ------------------------------------------
  AQP0         Contains Platin           1409    1.16 (1.01--1.34)   0.033[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     1.24 (1.03--1.5)    0.025[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol + Platin   776     1.28 (1.06--1.55)   0.012[\*](#T4TFN1){ref-type="table-fn"}
  AQP1         Contains Platin           1409    1.28 (1.09--1.49)   0.0022[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     1.25 (1.03--1.52)   0.026[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol + Platin   776     1.26 (1.03--1.54)   0.021[\*](#T4TFN1){ref-type="table-fn"}
  AQP3         Contains Platin           1409    0.82 (0.7--0.96)    0.014[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     0.76 (0.61--0.95)   0.016[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol + Platin   776     0.77 (0.62--0.96)   0.018[\*](#T4TFN1){ref-type="table-fn"}
  AQP4         Contains Platin           478     1.52 (1.13--2.03)   0.005[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            357     1.31 (0.98--1.74)   0.064
               Contains Taxol + Platin   356     1.32 (0.99--1.75)   0.06
  AQP5         Contains Platin           1409    0.85 (0.73--0.99)   0.033[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     1.15 (0.95--1.39)   0.14
               Contains Taxol + Platin   776     1.17 (0.96--1.41)   0.12
  AQP6/AQP2L   Contains Platin           1409    0.8 (0.7--0.93)     0.0023[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     0.79 (0.65--0.95)   0.013[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol + Platin   776     0.77 (0.63--0.94)   0.012[\*](#T4TFN1){ref-type="table-fn"}
  AQP8         Contains Platin           1409    0.86 (0.74--0.99)   0.038[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            793     0.84 (0.69--1.03)   0.096
               Contains Taxol + Platin   776     0.83 (0.68--1.02)   0.07
  AQP10        Contains Platin           478     0.74 (0.57--0.97)   0.027[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            357     1.32 (0.92--1.89)   0.14
               Contains Taxol + Platin   356     1.3 (0.91--1.86)    0.15
  AQP11        Contains Platin           478     0.74 (0.58--0.95)   0.017[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol            357     0.65 (0.48--0.89)   0.0067[\*](#T4TFN1){ref-type="table-fn"}
               Contains Taxol + Platin   356     0.65 (0.47--0.88)   0.0057[\*](#T4TFN1){ref-type="table-fn"}

*P*\<0.05.

In addition, [Table 2](#T2){ref-type="table"} showed the association between AQPs expression and clinical stages, in which *AQP3* (stage III + IV), *AQP8* (stage III + IV), *AQP10* (stage III + IV), and *AQP6/2L* (stages I + II and III + IV) mRNA expressions were significantly associated with favorable OS in ovarian cancer. Whereas AQP1 (stages I + II and III + IV), AQP4 (stages I + II and III + IV), and AQP5 (stage I + II) expressions revealed remarkably unfavorable OS in all ovarian cancer patients. However, AQP0 and AQP11 exhibited no correlation with any clinical stage of ovarian cancer.

While further assessing the prognostic significance between individual *AQPs* mRNA expression and TP53 mutation, AQP4 and AQP8 showed significantly poor OS in TP53-mutated ovarian cancer patients ([Table 3](#T3){ref-type="table"}), similarly AQP1 showed unfavorable OS in both TP53 mutated and wild ovarian cancer patients. However, AQP0, AQP3, AQP5, AQP6/2L, AQP10, and AQP11 revealed no correlation in both TP53 mutated and wild ovarian cancer patients.

Additionally, [Table 4](#T4){ref-type="table"} showed that *AQP6/AQP2L, AQP3*, and *AQP11* mRNA expression were correlated with better OS in all ovarian cancer patients treated with Platin, Taxol, and Taxol + Platin chemotherapeutic agents. AQP10, AQP5, and AQP8 were associated with improved OS in all patients treated with Platin chemotherapy, whereas AQP0 and AQP1 mRNA expression was associated with poor OS in all patients treated with Platin, Taxol, and Taxol + Platin chemotherapy. On the other hand, AQP4 expression was associated with unfavorable OS in all patients treated with Platin chemotherapy.

Discussion {#sec4}
==========

In the present study, we comprehensively retrieved the prognostic significance of individual *AQPs* mRNA expression in ovarian cancer by using the KM plotter. Amongst the members of AQPs family, only *AQP2* and *AQP9* mRNA had no effect on the OS of ovarian cancers, i.e. *AQP0, AQP1*, and *AQP4* mRNA expression were associated with poor OS, whereas high expression of AQP3, AQP5, AQP6, AQP8, AQP10, and AQP11 were associated with better OS for ovarian cancer patients.

In a previous study, reduced expression of water channels AQP2 was found to be correlated with cisplatin-induced polyuria and end-organ resistance in rats \[[@B23]\]. But so far, the role of AQP2 in cancers has not yet been explored. In the present study, we explored the prognostic significance of AQP2 in 1816 ovarian cancer patients by using the KM plotter database. Our results showed that high expression of *AQP2* mRNA had no effect on the prognosis of all ovarian cancer patients, serous ovarian cancer patients, as well as in endometrioid ovarian cancer patients. As for AQP9, Huang et al. \[[@B24]\] reported that AQP9 could serve as an independent predictive biomarker for adjuvant chemotherapy, and they demonstrated that high AQP9 expression was related to better disease-free survival in colorectal cancer patients treated with chemotherapy. However, the study of Tan et al. \[[@B25]\] indicated that the expression of both *AQP9* mRNA and protein was significantly up-regulated in astrocytic tumors and was positively associated with pathological grade, suggesting that AQP9 might play a critical role in the malignant progression of brain astrocytic tumors. Yang et al. \[[@B26]\] demonstrated that AQP9 protein expression in malignant and borderline tumors was significantly higher than in benign tumor and normal ovarian tissue. And high AQP9 expression level was found to be positively associated with tumor grade and histological type, they therefore proposed that overexpression of AQP9 might represent an important factor in ovarian carcinogenesis. Nevertheless, little is known about the prognostic value of AQP9 in ovarian cancer patients. In the present study, our data revealed that *AQP9* mRNA expression exhibited a null correlation with the prognosis in different histological types of ovarian cancer patients. Thus, the prognostic value of AQP2 and AQP9 in ovarian cancer needs further exploration.

To our knowledge, there was no study about the role of either AQP0 protein or mRNA in ovarian cancer, we conducted the first report on the prognostic significance of AQP0 in ovarian cancer. In our study, we demonstrated that high expression of *AQP0* mRNA was significantly associated with poor OS in all ovarian cancer patients. Several previous studies reported that high AQP1 expression was related to an unfavorable prognosis including cutaneous melanoma, pharyngeal carcinomas, urothelial carcinoma, and breast cancer \[[@B27]\]. In ovarian cancer, Yang et al. \[[@B31]\] found that high expression of AQP1 might play a key role in ovarian carcinogenesis, progression, and ascites formation. However, the prognostic value of AQP1 in ovarian cancer has not yet been studied. In our current study, we discovered overexpression of *AQP1* mRNA was associated with poor OS for all ovarian cancer patients, especially for serous ovarian cancer, with well and moderate differentiation (pathological grades I and II) as well as in all clinical stages (I--IV). As for AQP4, Sun et al. \[[@B32]\] revealed that AQP4 modulated not only water and ion homeostasis but also regulated the mechanism of ovarian hormone and neurotransmitter. Of note, earlier studies demonstrated that high AQP4 expression was associated with human glioma cancer development, suggesting that it triggered cell migration, invasion, and tumorigenesis \[[@B33],[@B34]\]. Although study has not mentioned about AQP4 correlation with ovarian cancer, consistent with the previous results, we documented that *AQP4* mRNA expression in ovarian cancer was correlated with poor prognosis to OS in all ovarian cancer, especially with the serous ovarian cancer type. Similarly, high AQP4 level showed markedly unfavorable prognosis both in well and poorly differentiated cancer and early (I + II) and advanced stage (III + IV) ovarian cancer. Based on previous evidences as well as our results, we can acknowledge that *AQP0, AQP1*, and *AQP4* high mRNA expression were significantly associated with poor prognosis in ovarian cancer patients.

Kang et al. \[[@B35]\] reported that overexpression of AQP3 was associated with a worse prognosis in patients with HER2-positive early breast cancer. In a study of patients with cervical carcinomas, Shi et al. \[[@B36]\] observed that the expression of AQP3 was significantly increased in larger tumor size, advanced stage, deeper infiltration, and metastatic lymph nodes. Thus, they indicated that AQP3 might play an important role in carcinogenesis and tumor progression of cervical carcinomas \[[@B36]\]. To our knowledge, the study of Yang et al. \[[@B37]\] was the first to show that the expression of AQP3 was increased in epithelial ovarian cancer from laying hens, which suggested that AQP3 may be a potential biomarker to predict the development and progression of epithelial cell-derived ovarian carcinomas in chickens. However, there is no publication reporting on the prognostic significance of AQP3 in human ovarian cancer. Intriguingly, our study found that *AQP3* mRNA expression significantly associated with better prognosis in all ovarian cancer patients, both in endometrioid and serous types ovarian cancer patients. Moreover, overexpression of *AQP3* mRNA speculated favorable OS in poor differentiation and advanced clinical stage ovarian cancer patients. Similarly, Zhang et al. \[[@B38]\] reported that AQP5 played a key role in cervical cancer and was linked with a worse prognosis in patients with cervical cancer. Furthermore, Yang et al. \[[@B39]\] showed that the expression of AQP5 protein and mRNA was positively correlated with ascites amount and lymph node metastasis, and they speculated that AQP5 might play a critical role in tumorigenesis of epithelial ovarian tumors. However, the study about the prognostic role of AQP5 in ovarian cancer has not been studied yet. Our results showed that *AQP5* mRNA expression was significantly associated with better OS in all ovarian cancer patients and well differentiated ovarian cancer patients. Taken together, our results indicated that high level of AQP3 and AQP5 might favor clinical outcomes in ovarian cancer.

Ma et al. \[[@B40]\] reported that the level of AQP6 was obviously decreased in serous ovarian cancer compared with normal tissues. Nonetheless, whether or not AQP6 has a prognostic role in ovarian cancer remained elusive. In this report, *AQP6* mRNA expression found to be associated with better OS in all ovarian cancer patients, mainly in endometrioid cancer patients, as well as in all clinical stages and poorly differentiated ovarian cancer. In addition, Ma et al. \[[@B40]\] showed that there was no significantly statistical difference in AQP8 expression between benign and malignant epithelial ovarian tumors. However, they demonstrated that the AQP8 expression was increased in patients with large volume of malignant ascites, suggesting that the clinical significance of AQP8 needed further study. In the preent study, we reported for the first time that high *AQP8* mRNA expression was associated with favorable OS for all the ovarian cancer patients and advanced stage (III + IV) ovarian cancer. Therefore, high *AQP6* and *AQP8* mRNA expression may predict a favorable prognosis in ovarian cancer.

Different from other AQPs, there was no previous study about the role of AQP10 and AQP11 in human malignant tumors. In the present study, we found that high expression of *AQP10* mRNA predicted a better prognosis in all ovarian cancer patients mostly with serous subtypes, well-differentiated pathological grade (grade I) and advanced stage (III + IV) ovarian cancer. In addition, we observed a better OS with higher *AQP11* mRNA expression in all ovarian cancer patients mainly with serous subtypes, as well as in poorly differentiated (grade III) cancer patients. In general, our results showed that the presence of *AQP10* and *AQP11* mRNA linked with positive outcomes in ovarian cancer patients.

Large family members of AQPs and mutation of a tumor suppressor gene have been considered as an essential driver in cancer onset and progression. *TP53* gene transcription regulators are extensively studied and highly mutated in various aspects of ovarian cancer. It is frequently located in early events, generally with high-grade serous ovarian cancers \[[@B41]\]. Additionally, study has suggested that activated p53 could regulate the expression of AQPs through p38 MAPK pathway and mediate the cytotoxic effects \[[@B42],[@B43]\]. Multiple evidences have revealed the correlation between p53 function and ovarian cancer stem cells, however, evidences about the prognostic association between TP53 status and AQP subtypes in ovarian cancer remains to be clarified. In our current analysis, we found that high level of *AQP1, AQP4*, and *AQP8* mRNA expression in TP53 mutation and *AQP1* mRNA expression in TP53 wild-type ovarian cancer patients were correlated with poor survival rate, indicating that mutation of *TP53* gene might regulate AQP1, AQP4, and AQP8 expression and participation in the development of ovarian caners.

Recently, AQPs were found to be permeable with arsenic and antimony compounds and took part in the detoxification pathway thereby conferring chemoresistance and sensitivity via transporting metalloids into cells \[[@B44]\]. It has been anticipated that finding AQP inhibitors of suitable affinity and specificity will generate highly acceptable pharmacological tools and contribute as a potential novel chemotherapeutic agent \[[@B47]\]. Xuejun et al. \[[@B48]\] suggested that AQPs were closely associated with other transmembrane transport channels, and thus played a vital role in cell apoptosis, drug metabolism, and chemosensitivity through water permeability regulation in ovarian cancer. In addition, they found different members of AQPs displayed various responses to chemotherapy in ovarian cancer cells. The relation between AQP signaling and carcinogenesis, as well as its cross-talk with multiple oncogenic signaling pathway implied that AQP signaling, mainly few AQP receptors might be a good candidate for drug target of ovarian cancer. In the present study, we observed that almost all studied AQPs submembers were correlated to the prognosis referring to Platin chemotherapeutic agent. In fact, *AQP0, AQP1*, and *AQP4* mRNA overexpression were associated with a poor prognosis with Platin therapy. However, *AQP3, AQP5, AQP6, AQP8, AQP10*, and *AQP11* high mRNA were associated with improved survival rate, implying that overexpression of these six AQP submembers increase drug sensitivity, probably through eliminating most infiltrative cells and increased intracellular accumulation of drugs which later permeated through special transmembrane transport system or extracellular hyperosmosis mechanism \[[@B44],[@B48],[@B49]\]. So far, the exact mechanism is unknown but abnormal expression of AQPs in hypertonic stress might have contributed to inhibit transmembrane transport of platinum ion in ovarian cancer cells \[[@B49]\]. In addition, confer to the Taxol-treated ovarian cancer patients, elevated *AQP4, AQP5, AQP8*, and *AQP10* mRNA expression illustrated no correlation, whereas increased expression of AQP0 and AQP1 revealed poor OS and increased expression of AQP3, AQP6, and AQP11 showed improved OS in ovarian cancer patients. Intriguingly, when concurrent (Platin + Taxol) treatment and prognostic significance were analyzed, the data showed that high expression of *AQP0* and *AQP1* mRNA were correlated to decrease survival rate and high expression of AQP3, AQP6, and AQP11 were correlated to good OS in ovarian cancer patients. In general, AQPs and its submembers might contribute to the overall survival, however, due to other independent function of regulatory transport mechanism of chemotherapeutic across cell membrane, it can be a significant therapeutic target in ovarian cancer patients, yet discrete significance of AQPs expression needs to be further explored in order to specify independent function.

Conclusion {#sec5}
==========

Based on the above-mentioned comprehensive survival analysis platforms of KM plotter, our results showed that six members of *AQPs* (*AQP3, AQP5, AQP6, AQP8, AQP10*, and *AQP11*) mRNA expression were significantly correlated to favorable OS in ovarian cancer patients, whereas *AQP0, AQP1*, and *AQP4* mRNA were associated with poor survival in ovarian cancer patients. In addition, high level of AQPs have been detected with essential prognostic effects in Platin, Taxol, and concurrent-based chemotherapy in ovarian cancer. We also observed that specific AQPs were associated with the pivotal role in the prognosis of early and advanced clinical stages, different pathological grade, and TP53 status in ovarian cancer patients. These results indicated that individual AQPs, except AQP2 and AQP9, were associated with unique prognostic significance and thus might act as new predictive prognostic indicators in ovarian cancer. Even though our findings were statistically significant, large family members of aquaporin genes need future studies to establish the regulatory pathway of specific AQPs in carcinogenesis, tumor progression and invasion of ovarian cancer. Current study provided new insights regarding the contribution of AQPs subtypes into ovarian cancer progression and might help to explore the further discovery of AQPs to contribute as an accurate and strong cancer prognostic predictor and develop as a potential drug therapeutic target.
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